- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05878691
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jatin Kadam
- Phone Number: 02250451200
- Email: clinicaltrialsdisclosuredesk@glenmarkpharma.com
Study Locations
-
-
-
Delhi, India, 110017
- Not yet recruiting
- Max Superspeciality Hospital
-
-
Andhra Pradesh
-
Vijayawada, Andhra Pradesh, India, 520002
- Recruiting
- HCG City Cancer Centre
-
Visakhapatnam, Andhra Pradesh, India, 530017
- Recruiting
- Mahatma Gandhi Cancer Hospital and Research Institute
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Recruiting
- Artemis Hospital
-
-
Karnataka
-
Bangalore, Karnataka, India, 5600027
- Recruiting
- Health Care Global Enterprises Ltd (HCG)
-
Bangalore, Karnataka, India, 560066
- Recruiting
- Vydehi Hospital
-
Bengaluru, Karnataka, India, 560064
- Recruiting
- Cytecare Hospitals Pvt Ltd.
-
Bengaluru, Karnataka, India, 560092
- Recruiting
- Aster CMI Hospital
-
-
Kerala
-
Kannur, Kerala, India, 670103
- Recruiting
- Malabar Cancer Centre
-
-
Maharashtra
-
Aurangabad, Maharashtra, India, 431001
- Recruiting
- Krupamayi Hospitals
-
Mumbai, Maharashtra, India, 400052
- Recruiting
- PD Hinduja Hospital and Medical Research Centre
-
Nashik, Maharashtra, India, 422002
- Recruiting
- HCG Manavata Cancer Centre
-
Nashik, Maharashtra, India, 422009
- Recruiting
- Sankalp Hospital
-
Thāne, Maharashtra, India, 401107
- Active, not recruiting
- Bhaktivedanta Hospital and Research Institute
-
-
Telangana
-
Hyderabad, Telangana, India, 500034
- Recruiting
- Basavatarakam Indo American Cancer Hospital Research Institute
-
Hyderabad, Telangana, India, 500032
- Recruiting
- AIG Hospitals, (A unit of asian Institute of Gastroenterology)
-
-
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Carolina BioOncology Institute
-
Contact:
- John D. Powderly II, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226-1222
- Recruiting
- Froedtert & Medical College of Wisconsin - Froedtert Hospital - Clinical Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects (≥18 years of age) with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors or lymphomas who have previously received standard systemic therapy or for whom treatment is not accessible, not tolerated or refused, have progressed after ≥1 of systemic therapies for recurrent/metastatic disease and who have not received prior therapy targeting HPK1.
- At least 1 measurable lesion as defined per RECIST 1.1. The target lesion(s) selected have not been previously treated with local therapy or the target lesion(s) selected that are within the field of prior local therapy have subsequently progressed as defined by RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1 measured within 72 hours of treatment.
- Predicted life expectancy of ≥3 months.
- Adequate organ function as indicated by the following laboratory values up to first dose of study drug: Hemoglobin ≥9.0 g/dL, Absolute neutrophil count ≥1.5 x 109/L, Serum total bilirubin ≤1.5 x ULN (<3 x ULN for participants with Gilbert syndrome), AST and ALT ≤2.5 x ULN (≤5 x ULNs for participants with hepatocellular carcinoma or liver metastases).
- Adequate renal function as indicated by creatinine clearance of ≥60mL/min calculated using Cokroft-Gault method.
- Adequate cardiac function, left ventricular ejection fraction (LVEF) of ≥50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO).
- For Part 2, dose expansion cohorts inclusion criteria specific to tumor types will be updated after completion of Part 1.
Exclusion Criteria:
- Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results.
- Subjects with uncontrolled or untreated brain metastasis or leptomeningeal disease. Subjects with equivocal findings or with confirmed brain metastases are eligible provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for at least 4 weeks prior to the first dose of study drug(s)
- Any active malignancy ≤2 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast)
Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first dose of study drug(s), with the following exceptions:
- Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)
- Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
- Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)
- Pregnant/planning to be pregnant or breast-feeding women.
- Any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study (based on the investigator's judgment).
- Any known severe allergic reaction to pembrolizumab/atezolizumab or its excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GRC 54276
|
Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle. Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm. |
Experimental: GRC 54276 with pembrolizumab
|
Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days. Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm. |
Experimental: GRC 54276 with atezolizumab
|
Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days. Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities to establish the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Time Frame: 18 weeks
|
Percentage of participants with dose limiting toxicities associated with GRC54276 alone or GRC54276 combined with pembrolizumab or atezolizumab during the first cycle.
Toxicity will be assessed using the NCI CTCAE Version 5.0.
|
18 weeks
|
Incidence of treatment-emergent adverse events and serious adverse events
Time Frame: up to 120 days
|
Percentage of participants who experience treatment-emergent adverse events and serious adverse events when given GRC54276 as a single agent and in combination with pembrolizumab or atezolizumab.
|
up to 120 days
|
Changes in the laboratory safety values from baseline to end of safety follow-up
Time Frame: up to 120 days
|
Percentage of participants who experience changes in the laboratory safety values when given GRC54276 as a single agent and in combination with pembrolizumab or atezolizumab.
|
up to 120 days
|
Pharmacokinetic profile of GRC54276- Maximum plasma concentration (Cmax)
Time Frame: up to 22 days
|
The maximum measured plasma concentration after single or multiple dosing, tabulated by dose group and day of dosing.
|
up to 22 days
|
Pharmacokinetic profile of GRC54276- Time to Cmax (Tmax)
Time Frame: up to 22 days
|
The time to achieve Cmax after single or multiple dosing, tabulated by dose group and day of dosing.
|
up to 22 days
|
Pharmacokinetic profile of GRC54276- Area under the curve (AUC)
Time Frame: up to 22 days
|
Area under plasma concentration versus time curve from time 0 to time of least measurable concentration or the dosing interval, tabulated by dose group and day of dosing.
|
up to 22 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: up to 9 months
|
Proportion of participants with a best response of complete response or partial response best on RECIST 1.1.
|
up to 9 months
|
Best overall response rate
Time Frame: up to 9 months
|
Complete response, partial response, stable disease, and progressive disease, evaluated according to RECIST 1.1.
|
up to 9 months
|
Disease control rate
Time Frame: up to 9 months
|
The percentage of participants who have achieved stable disease or complete response or partial response according to RECIST 1.1.
for the entire duration of the study.
|
up to 9 months
|
Duration of response
Time Frame: up to 9 months
|
The time from first documentation of complete response or partial response to the first documentation of progression.
|
up to 9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Harsha Doddihal, MD, Glenmark Pharmaceuticals Ltd.
- Study Director: Adam Y-Beltran, MD, Glenmark Pharmaceuticals Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Atezolizumab
Other Study ID Numbers
- GRC 54276-101
- CTRI/2022/05/042484 (Registry Identifier: Clinical Trials Registry-India)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
Ruijin HospitalThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsNot yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-TypeChina
Clinical Trials on GRC 54276
-
Glenmark Pharmaceuticals S.A.Completed
-
Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.WithdrawnPainful Diabetic NeuropathyGermany, United Kingdom
-
Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.CompletedPainful Diabetic Peripheral NeuropathyIndia, Czech Republic, Germany, United Kingdom
-
Forest LaboratoriesCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Glenmark Pharmaceuticals Europe Ltd. (R&D)Unknown
-
Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.Completed
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Terminated